Danaher (NYSE:DHR) PT Raised to $290.00 at TD Cowen

Danaher (NYSE:DHR) had its price objective boosted by TD Cowen from $280.00 to $290.00 in a report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the conglomerate’s stock.

A number of other research firms have also recently commented on DHR. StockNews.com cut shares of Danaher from a buy rating to a hold rating in a report on Wednesday, January 31st. Robert W. Baird upped their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an outperform rating in a report on Wednesday. KeyCorp upped their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an overweight rating in a report on Thursday, February 1st. Royal Bank of Canada upped their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an outperform rating in a report on Wednesday, January 31st. Finally, HSBC raised shares of Danaher from a hold rating to a buy rating and upped their price objective for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $269.64.

Danaher Trading Up 0.3 %

DHR stock opened at $246.58 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00. The stock has a market capitalization of $182.64 billion, a price-to-earnings ratio of 41.79, a price-to-earnings-growth ratio of 3.79 and a beta of 0.83. The firm’s fifty day simple moving average is $248.87 and its two-hundred day simple moving average is $231.16.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.36 earnings per share. As a group, analysts anticipate that Danaher will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date was Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Insider Buying and Selling

In related news, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 106,565 shares of company stock worth $26,641,364. 11.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Riverwater Partners LLC lifted its position in shares of Danaher by 58.9% during the 1st quarter. Riverwater Partners LLC now owns 3,571 shares of the conglomerate’s stock valued at $892,000 after buying an additional 1,323 shares in the last quarter. James Hambro & Partners lifted its holdings in Danaher by 9.8% in the 1st quarter. James Hambro & Partners now owns 250,443 shares of the conglomerate’s stock valued at $62,493,000 after purchasing an additional 22,438 shares in the last quarter. Conning Inc. lifted its holdings in Danaher by 1.3% in the 1st quarter. Conning Inc. now owns 22,930 shares of the conglomerate’s stock valued at $5,726,000 after purchasing an additional 292 shares in the last quarter. K.J. Harrison & Partners Inc lifted its holdings in Danaher by 20.8% in the 1st quarter. K.J. Harrison & Partners Inc now owns 11,820 shares of the conglomerate’s stock valued at $2,952,000 after purchasing an additional 2,034 shares in the last quarter. Finally, McGuire Investment Group LLC lifted its holdings in Danaher by 0.8% in the 1st quarter. McGuire Investment Group LLC now owns 34,962 shares of the conglomerate’s stock valued at $8,731,000 after purchasing an additional 294 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.